Cargando…

Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient

BACKGROUND: Speciation of arsenic trioxide (ATO) metabolites in clinical samples such as peripheral blood (PB) from acute promyelocytic leukemia (APL) patients has been conducted. However, speciation of arsenicals in bone marrow (BM) has not yet been performed. Profiles of arsenic speciation in plas...

Descripción completa

Detalles Bibliográficos
Autores principales: Iriyama, Noriyoshi, Yoshino, Yuta, Yuan, Bo, Horikoshi, Akira, Hirabayashi, Yukio, Hatta, Yoshihiro, Toyoda, Hiroo, Takeuchi, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293031/
https://www.ncbi.nlm.nih.gov/pubmed/22272800
http://dx.doi.org/10.1186/1756-8722-5-1
_version_ 1782225356270338048
author Iriyama, Noriyoshi
Yoshino, Yuta
Yuan, Bo
Horikoshi, Akira
Hirabayashi, Yukio
Hatta, Yoshihiro
Toyoda, Hiroo
Takeuchi, Jin
author_facet Iriyama, Noriyoshi
Yoshino, Yuta
Yuan, Bo
Horikoshi, Akira
Hirabayashi, Yukio
Hatta, Yoshihiro
Toyoda, Hiroo
Takeuchi, Jin
author_sort Iriyama, Noriyoshi
collection PubMed
description BACKGROUND: Speciation of arsenic trioxide (ATO) metabolites in clinical samples such as peripheral blood (PB) from acute promyelocytic leukemia (APL) patients has been conducted. However, speciation of arsenicals in bone marrow (BM) has not yet been performed. Profiles of arsenic speciation in plasma of BM were thus investigated and compared with those of PB plasma from a relapsed APL patient. The total arsenic concentrations in high molecular weight fraction (HMW-F) of BM and PB plasma were also determined. METHODS: Response assessment was evaluated by BM aspirate examination and fluorescence in situ hybridization analysis. The analyses of total arsenic concentrations and speciation were preformed by inductively coupled plasma mass spectrometry (ICP-MS), and high-performance liquid chromatography (HPLC)/ICP-MS, respectively. RESULTS: Response assessment showed that the patient achieved complete remission. The total arsenic concentrations in BM plasma increased with time during the consecutive administration. The PB plasma concentrations of methylated arsenic metabolites substantially increased after the start of administration, while those of inorganic arsenic were still kept at a low level, followed by substantially increase from day-14 after administration. The arsenic speciation profiles of PB plasma were very similar to those of BM plasma. Furthermore, the total arsenic concentrations of HMW-F in BM plasma were much higher than those in PB plasma. CONCLUSIONS: The behaviors of arsenic speciation suggested for the first time that arsenic speciation analysis of PB plasma could be predicative for BM speciation, and showed relatively higher efficiency of drug metabolism in the patient. These results may further provide not only significance of clinical application of ATO, but also a new insight into host defense mechanisms in APL patients undergoing ATO treatment, since HMW proteins-bound arsenic complex could be thought to protect BM from the attack of free arsenic species.
format Online
Article
Text
id pubmed-3293031
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32930312012-03-05 Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient Iriyama, Noriyoshi Yoshino, Yuta Yuan, Bo Horikoshi, Akira Hirabayashi, Yukio Hatta, Yoshihiro Toyoda, Hiroo Takeuchi, Jin J Hematol Oncol Research BACKGROUND: Speciation of arsenic trioxide (ATO) metabolites in clinical samples such as peripheral blood (PB) from acute promyelocytic leukemia (APL) patients has been conducted. However, speciation of arsenicals in bone marrow (BM) has not yet been performed. Profiles of arsenic speciation in plasma of BM were thus investigated and compared with those of PB plasma from a relapsed APL patient. The total arsenic concentrations in high molecular weight fraction (HMW-F) of BM and PB plasma were also determined. METHODS: Response assessment was evaluated by BM aspirate examination and fluorescence in situ hybridization analysis. The analyses of total arsenic concentrations and speciation were preformed by inductively coupled plasma mass spectrometry (ICP-MS), and high-performance liquid chromatography (HPLC)/ICP-MS, respectively. RESULTS: Response assessment showed that the patient achieved complete remission. The total arsenic concentrations in BM plasma increased with time during the consecutive administration. The PB plasma concentrations of methylated arsenic metabolites substantially increased after the start of administration, while those of inorganic arsenic were still kept at a low level, followed by substantially increase from day-14 after administration. The arsenic speciation profiles of PB plasma were very similar to those of BM plasma. Furthermore, the total arsenic concentrations of HMW-F in BM plasma were much higher than those in PB plasma. CONCLUSIONS: The behaviors of arsenic speciation suggested for the first time that arsenic speciation analysis of PB plasma could be predicative for BM speciation, and showed relatively higher efficiency of drug metabolism in the patient. These results may further provide not only significance of clinical application of ATO, but also a new insight into host defense mechanisms in APL patients undergoing ATO treatment, since HMW proteins-bound arsenic complex could be thought to protect BM from the attack of free arsenic species. BioMed Central 2012-01-24 /pmc/articles/PMC3293031/ /pubmed/22272800 http://dx.doi.org/10.1186/1756-8722-5-1 Text en Copyright ©2012 Iriyama et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Iriyama, Noriyoshi
Yoshino, Yuta
Yuan, Bo
Horikoshi, Akira
Hirabayashi, Yukio
Hatta, Yoshihiro
Toyoda, Hiroo
Takeuchi, Jin
Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient
title Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient
title_full Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient
title_fullStr Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient
title_full_unstemmed Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient
title_short Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient
title_sort speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293031/
https://www.ncbi.nlm.nih.gov/pubmed/22272800
http://dx.doi.org/10.1186/1756-8722-5-1
work_keys_str_mv AT iriyamanoriyoshi speciationofarsenictrioxidemetabolitesinperipheralbloodandbonemarrowfromanacutepromyelocyticleukemiapatient
AT yoshinoyuta speciationofarsenictrioxidemetabolitesinperipheralbloodandbonemarrowfromanacutepromyelocyticleukemiapatient
AT yuanbo speciationofarsenictrioxidemetabolitesinperipheralbloodandbonemarrowfromanacutepromyelocyticleukemiapatient
AT horikoshiakira speciationofarsenictrioxidemetabolitesinperipheralbloodandbonemarrowfromanacutepromyelocyticleukemiapatient
AT hirabayashiyukio speciationofarsenictrioxidemetabolitesinperipheralbloodandbonemarrowfromanacutepromyelocyticleukemiapatient
AT hattayoshihiro speciationofarsenictrioxidemetabolitesinperipheralbloodandbonemarrowfromanacutepromyelocyticleukemiapatient
AT toyodahiroo speciationofarsenictrioxidemetabolitesinperipheralbloodandbonemarrowfromanacutepromyelocyticleukemiapatient
AT takeuchijin speciationofarsenictrioxidemetabolitesinperipheralbloodandbonemarrowfromanacutepromyelocyticleukemiapatient